AstraZeneca shares climbed sharply in London trading after the pharmaceutical group reported stronger-than-expected first-half results, buoyed by robust demand for its oncology portfolio.
The British giant posted revenues of £23 billion for the six months ended June 30, a 6% increase year-over-year, while profits rose 2% to £5 billion.
Chief Executive Pascal Soriot highlighted the sustained momentum in sales of key cancer treatments as a primary driver of the outperformance.
The market reaction underscores investor appetite for pharmaceutical companies with proven growth engines in high-margin therapeutic areas.
AstraZeneca’s ability to deliver top-line growth alongside profit expansion suggests effective cost management and pricing power in its core markets.
The stock’s advance reflects a repricing of near-term earnings potential, with traders positioning for continued strength in the second half of the year.